NASDAQ · SABS
Healthcare · Biotechnology
$3.39
Up+$0.11 (+3.24%)
Updated Sep 17, 2026, 11:06 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SABS closed at $3.39 after 20 trading sessions, down 10.32% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.45 | $3.49 | $3.35 | $3.39 | 452.39K |
| Sep 15, 2026 | $3.45 | $3.5082 | $3.32 | $3.41 | 284.26K |
| Sep 14, 2026 | $3.42 | $3.51 | $3.395 | $3.46 | 237.5K |
| Sep 11, 2026 | $3.45 | $3.54 | $3.38 | $3.41 | 712.05K |
| Sep 10, 2026 | $3.48 | $3.53 | $3.395 | $3.42 | 328.63K |
| Sep 9, 2026 | $3.61 | $3.65 | $3.47 | $3.48 | 200.97K |
| Sep 8, 2026 | $3.70 | $3.75 | $3.62 | $3.63 | 171.26K |
| Sep 4, 2026 | $3.72 | $3.75 | $3.695 | $3.72 | 110.63K |
| Sep 3, 2026 | $3.76 | $3.79 | $3.71 | $3.72 | 161.59K |
| Sep 2, 2026 | $3.70 | $3.77 | $3.60 | $3.75 | 300.42K |
| Sep 1, 2026 | $3.65 | $3.749 | $3.65 | $3.70 | 202.28K |
| Aug 31, 2026 | $3.76 | $3.80 | $3.69 | $3.71 | 201.14K |
| Aug 28, 2026 | $3.91 | $3.99 | $3.785 | $3.79 | 202.6K |
| Aug 27, 2026 | $3.86 | $3.93 | $3.835 | $3.93 | 282.22K |
| Aug 26, 2026 | $3.80 | $3.90 | $3.75 | $3.88 | 274.42K |
| Aug 25, 2026 | $3.65 | $3.81 | $3.61 | $3.81 | 359.37K |
| Aug 24, 2026 | $3.78 | $3.78 | $3.61 | $3.62 | 602.69K |
| Aug 21, 2026 | $3.74 | $3.83 | $3.70 | $3.78 | 195.67K |
| Aug 20, 2026 | $3.75 | $3.7607 | $3.66 | $3.70 | 229.63K |
| Aug 19, 2026 | $3.83 | $3.88 | $3.76 | $3.78 | 701.27K |
The latest Smart Investors Daily articles mentioning SABS.
SABS research
Company profile and research snapshot.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 24, 2026 | Barclays | Overweight | — |
| Jun 17, 2026 | Chardan Capital | Buy | — |
| Jun 15, 2026 | Leerink Partners | Outperform | — |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | — |
| May 22, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 7, 2026
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human
globenewswire.com · Dec 8, 2025
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SABS.
